Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA approves Biocompatibles' OC OTW (over-the-wire) stent:

This article was originally published in Clinica

Executive Summary

The US FDA has approved for sale Biocompatibles International's BiodivYsio OC over-the-wire (OTW) coronary stent. The device is available in a variety of lengths - ranging from 11mm to 28mm - on OTW delivery systems of 3mm, 3.5mm and 4mm in diameter. The product completes the company's current BiodivYsio coronary stent product line, which includes the US-approved Added Support and the Small Vessel OTW stents. Biocompatibles' stents are coated with the Farnham, Surrey firm's phosphorylcholine (PC) technology - a biocompatible coating that reduces the body's response to medical devices. Abbott Laboratories is the US distributor of Biocompatibles' cardiovascular line.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT065037

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel